1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.

2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.

3. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.

4. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.

5. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014;311:1143-9.

6. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 2016;70:740-8.

7. Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer Prostatic Dis 2018; doi: 10.1038/s41391-018-0076-3.

8. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-9.

9. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.

10. Yang J, Zhu Y, Guo H, Wang X, Gao R, et al. Identifying serum biomarkers for ovarian cancer by screening with surface-enhanced laser desorption/ionization mass spectrometry and the artificial neural network. Int J Gynecol Cancer 2013;23:667-72.

11. Wright GL Jr, Cazares LH, Leung SM, Nasim S, Adam BL, et al. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2:264-76.

12. Ocak S, Chaurand P, Massion PP. Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 2009;6:159-70.

13. Martínez-Aguilar J, Chik J, Nicholson J, Semaan C, McKay MJ, et al. Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin Appl 2013;7:42-54.

14. Wu B, Abbott T, Fishman D, McMurray W, Mor G, et al. Ovarian cancer classification based on mass spectrometry analysis of sera. Cancer Inform 2007;2:123-32.

15. Nizioł J, Ossoliński K, Ossoliński T, Ossolińska A, Bonifay V, et al. Surface-transfer mass spectrometry imaging of renal tissue on gold nanoparticle enhanced target. Anal Chem 2016;88:7365-71.

16. Whelan SA, He J, Lu M, Souda P, Saxton RE, et al. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. J Proteome Res 2012;11:5034-45.

17. Xue R, Dong L, Zhang S, Deng C, Liu T, et al. Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:1181-6.

18. Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, et al. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev Mol Diagn 2015;15:1211-24.

19. Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Res 2015;35:1017-23.

20. de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygård O, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer - a large nested case-control study within the JANUS cohort in Norway. Int J Cancer 2014;134:197-206.

21. de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Galasso G, et al. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol 2015;33:201.

22. Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, et al. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget 2017;8:18424-34.

23. Sekuła J, Nizioł J, Rode W, Ruman T. Gold nanoparticle-enhanced target (AuNPET) as universal solution for laser desorption/ionization mass spectrometry analysis and imaging of low molecular weight compounds. Anal Chim Acta 2015;875:61-72.

24. Cacciatore S, Zadra G, Bango C, Penney KL, Tyekucheva S, et al. Metabolic profiling in formalin-fixed and paraffin-embedded prostate cancer tissues. Mol Cancer Res 2017;15:439-47.

25. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.

26. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.

27. Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res 2010;30:369-74.

28. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016;5:e189.

29. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-11.

30. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One 2012;7:e30062.

31. Twiddy AL, Leon CG, Wasan KM. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 2011;28:423-37.

32. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.

33. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, et al. Cholesterol metabolism and prostate cancer lethality. Cancer Res 2016;76:4785-90.

34. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 2014;23:2349-56.

35. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009;18:2807-13.

36. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2009;21:61-8.

37. Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, et al. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis 2011;14:340-5.

38. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316-20.

39. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008;123:1693-8.

40. Eberlin LS, Dill AL, Costa AB, Ifa DR, Cheng L, et al. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem 2010;82:3430-4.

41. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.

42. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6:551-62.

43. Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. Br J Cancer 2015;113:1712-9.

44. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res 2012;18:3677-85.

45. Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. J Epidemiol 2015;25:261-74.

46. Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res 2014;20:2289-99.

47. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 2011;131:1187-96.

48. Ben-Eltriki M, Deb S, Guns ES. Calcitriol in combination therapy for prostate cancer: pharmacokinetic and pharmacodynamic interactions. J Cancer 2016;7:391-407.

49. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 2012;97:2315-24.

50. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25:669-74.

51. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 2007;22:V74-80.

52. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005;97:31-6.

53. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, et al. Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559.

54. Davies O, Mendes P, Smallbone K, Malys N. Characterisation of multiple substrate-specific (d)ITP/(d)XTPase and modelling of deaminated purine nucleotide metabolism. BMB Rep 2012;45:259-64.

55. Ji D, Stepchenkova EI, Cui J, Menezes MR, Pavlov YI, et al. Measuring deaminated nucleotide surveillance enzyme ITPA activity with an ATP-releasing nucleotide chimera. Nucleic Acids Res 2017;45:11515-24.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: